IBS-C Treatment: Why Bloating Persists & Solutions

IBS-C Constipation Treatment Management: Why Bloating Persists and What Works

A 2026 review from Mayo Clinic and Cedars-Sinai researchers confirms a frustrating reality for many patients: treating constipation does not always resolve bloating. This persistent bloating signals that irritable bowel syndrome with constipation (IBS-C) often requires a more targeted approach than simply improving stool frequency. Evidence now strongly supports a management strategy that first identifies the specific driver of symptoms in each individual.

Bloating as a Distinct Symptom with Complex Roots

David Cangemi and colleagues from the Mayo Clinic clarify that bloating is a “relatively nonspecific symptom with a complex pathophysiology.” Its presence alongside constipation means clinicians must differentiate between primary diagnoses like IBS-C, chronic idiopathic constipation (CIC), pelvic floor dysfunction, and intestinal methanogen overgrowth (IMO). While constipation can cause bloating from retained stool and gas, the bloating may also stem from visceral hypersensitivity, altered gas handling by the gut, or microbial fermentation. This explains why a laxative that moves stool might leave a patient’s distension and discomfort unchanged. The researchers emphasize that personalized management starts with understanding which of these mechanisms is dominant for the patient.

Evidence Supports Secretagogues for Dual Symptom Relief

The review highlights a specific class of FDA-approved prescription drugs as a first-line pharmacologic option. Guanylate cyclase-C (GC-C) agonists, such as plecanatide and linaclotide, work by increasing fluid secretion into the intestinal lumen, which softens stool and accelerates transit. Large randomized trials demonstrate these drugs improve both constipation and bloating in IBS-C. They act locally in the gut with minimal systemic absorption. Another secretagogue, lubiprostone, activates chloride channels to achieve a similar effect. The sodium-hydrogen exchanger 3 inhibitor tenapanor is also noted for its dual benefit. This evidence confirms that targeting the underlying physiology of constipation can, for many, alleviate the accompanying bloating.

When First-Line Therapy Fails: The Role of Diet and Biofeedback

If bloating remains after addressing constipation, the pathophysiology is likely distinct. Here, the research points to two critical interventions. First, the review suggests a trial of dietary restriction, specifically a low-FODMAP diet. This reduces fermentable carbohydrates that gut bacteria convert into gas, directly targeting a primary cause of bloating. Second, Cangemi’s team states pelvic floor physical therapy with biofeedback “should be considered” for patients with dyssynergic defecation—a condition where the pelvic muscles contract instead of relax during a bowel movement. This dysfunction causes constipation and trapped gas, leading to bloating that standard medications cannot fix. As explored in our article on IBS-C Management: Beyond Laxatives for Gut-Brain Health, this neuromuscular retraining is a cornerstone of treatment for this subset.

Targeted Antibiotics Address Microbial Drivers of IBS-C

Supporting this multi-diagnosis model, a separate 2026 study by Iftequar and colleagues provides data on the microbial component. Their work confirms that small intestinal bacterial overgrowth (SIBO), and particularly its methane-producing variant (IMO), is a common find across IBS subtypes. For patients with IBS-C and a positive breath test, targeted antibiotic therapy is effective. The non-systemic antibiotic rifaximin is the primary choice, often combined with neomycin or metronidazole for methane-dominant cases. Eradicating this overgrowth can lead to significant improvements in both bloating and constipation, underscoring why testing and treating SIBO/IMO is a vital step in a comprehensive multi-cause, multi-target approach to IBS-C.

Conclusion

Effective management of IBS-C with bloating requires moving beyond a singular focus on constipation. Current evidence mandates a diagnostic process that separates overlapping conditions. A treatment sequence starting with proven secretagogues, then strategically incorporating Low FODMAP diet, biofeedback, or targeted antibiotics based on individual patient physiology, offers the best path to relieving this complex and burdensome symptom pair.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42319080/
https://pubmed.ncbi.nlm.nih.gov/42310284/
https://pubmed.ncbi.nlm.nih.gov/42283961/